

Table SV. Analysis of the immunostained skin biopsies of psoriatic patients' lesional skin before and after treatment

Antibody/ localization	Before treatment		After treatment		<i>p</i> -value ^c (before vs. after)	
	Combination ^a (<i>n</i> = 5)	Monotherapy ^b (<i>n</i> = 5)	Combination (<i>n</i> = 5)	Monotherapy (<i>n</i> = 5)	Combination	Monotherapy
<i>Immunopositive cells</i>						
IL-17A/epidermis	0 (0-0.5) ^d	0 (0-0.5)	0 (0-0)	0 (0-1.0)	1.000	1.000
IL-17A/dermis	8.3 (7.25-23.2)	6.5 (4.0-13.3)	12.0 (5.5-16.3)	12.5 (3.5-14.3)	0.875	1.000
CD3/epidermis	45.0 (15.5-58.0)	15.0 (13.0-36.0)	5.0 (1.5-36.5)	23.0 (15.0-25.0)	0.188	0.875
CD3/dermis	70.3 (54.25-119.5)	90.5 (37.5-103.25)	50.0 (23.8-74.5)	70.5 (40.25-96.5)	0.063	0.813
CD4/epidermis	9.0 (4.0-21.0)	5.0 (5.0-9.5)	2.0 (0.5-3.75)	6.0 (3.0-14.0)	0.063	1.000
CD4/dermis	150.0 (83.5-205.75)	117.0 (87.75-159.0)	61.5 (36.75-188.0)	72.0 (48.75-148.25)	0.438	0.625
CD8/epidermis	15.5 (9.0-41.0)	14.5 (7.25-43.0)	3.0 (1.25-14.0)	11.0 (3.5-33.25)	0.063	1.000
CD8/dermis	38.0 (24.0-61.1)	45.0 (40.5-57.5)	33.5 (5.17-55.5)	45.0 (29.5-57.0)	0.313	0.625
FoxP3/epidermis	3.0 (0.5-12.0)	2.0 (1.0-5.5)	0.0 (0.0-4.0)	1.0 (0.5-4.0)	0.125	0.625
FoxP3/dermis	47.5 (22.0-61.5)	22.0 (5.5-49.75)	22.5 (12.75-38.0)	22.5 (12.7-36.75)	0.313	0.625
<i>Immunopositive keratinocyte nuclei</i>						
GR α /epidermis	80.0 (70.0-92.5) ^e	80.0 (70.0-87.5)	60.0 (50.0-77.5)	70.0 (57.5-77.5)	0.250	0.063
GR β /epidermis	50.0 (42.5-62.5)	60.0 (47.5-62.5)	45.0 (30.0-50.0)	55.0 (40.0-60.0)	0.250	0.500

^aCombination: combination of calcipotriol/betamethasone. ^bMonotherapy: betamethasone. ^c*p*-values are calculated by Wilcoxon signed-rank test. ^dThe number of immunopositive cells /20 \times field image; median (interquartile range). ^ePercentage of immunopositive keratinocyte nuclei; median (interquartile range).